Interrogating SAR in Medical Chemistry

This lecture introduces the fundamentals of medicinal chemistry, focusing on the interrogation of Structure-Activity Relationships (SAR) in drug design. Topics include the multidisciplinary nature of medicinal chemistry, the limited synthetic toolbox available to med chemists, the importance of high-throughput screening (HTS) in lead discovery, and key milestones to reduce late-stage attrition of drug candidates. The lecture also covers the concepts of reversible vs. irreversible binders, compound selectivity in SAR evaluations, and the considerations for setting up small-molecule HTS. Practical examples and case studies are used to illustrate these concepts.

About this result

This page is automatically generated and may contain information that is not correct, complete, up-to-date, or relevant to your search query. The same applies to every other page on this website. Please make sure to verify the information with EPFL's official sources.

Related lectures (15)

Related concepts (217)

CH-332: Medicinal chemistry

Sitting at the crossroad of organic chemistry and medicine, this course outlines how an initial hit compound transitions into a lead candidate, and ultimately a drug, in the modern drug discovery worl

Hit to lead

Hit to lead (H2L) also known as lead generation is a stage in early drug discovery where small molecule hits from a high throughput screen (HTS) are evaluated and undergo limited optimization to identify promising lead compounds. These lead compounds undergo more extensive optimization in a subsequent step of drug discovery called lead optimization (LO).

Drug discovery

In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which new candidate medications are discovered. Historically, drugs were discovered by identifying the active ingredient from traditional remedies or by serendipitous discovery, as with penicillin. More recently, chemical libraries of synthetic small molecules, natural products or extracts were screened in intact cells or whole organisms to identify substances that had a desirable therapeutic effect in a process known as classical pharmacology.

Structure–activity relationship

The structure–activity relationship (SAR) is the relationship between the chemical structure of a molecule and its biological activity. This idea was first presented by Crum-Brown and Fraser in 1865. The analysis of SAR enables the determination of the chemical group responsible for evoking a target biological effect in the organism. This allows modification of the effect or the potency of a bioactive compound (typically a drug) by changing its chemical structure.

Drug design

Drug design, often referred to as rational drug design or simply rational design, is the inventive process of finding new medications based on the knowledge of a biological target. The drug is most commonly an organic small molecule that activates or inhibits the function of a biomolecule such as a protein, which in turn results in a therapeutic benefit to the patient. In the most basic sense, drug design involves the design of molecules that are complementary in shape and charge to the biomolecular target with which they interact and therefore will bind to it.

Medicinal chemistry

Medicinal or pharmaceutical chemistry is a scientific discipline at the intersection of chemistry and pharmacy involved with designing and developing pharmaceutical drugs. Medicinal chemistry involves the identification, synthesis and development of new chemical entities suitable for therapeutic use. It also includes the study of existing drugs, their biological properties, and their quantitative structure-activity relationships (QSAR).

Interrogating SAR: Medicinal Chemistry

Covers medicinal chemistry basics, high-throughput screening, lead discovery milestones, and compound selectivity in drug optimization.

Deep Generative Models in Drug Discovery ChE-605: AI in chemistry and beyond:Highlights in the field

Explores the application of deep generative models in drug discovery, focusing on designing small molecules and optimizing molecular structures.

Preclinical Animal Models: Selection & Rationale CH-332: Medicinal chemistry

Explores the selection and rationale of preclinical animal models in drug development, emphasizing the 10 to 15-year path to a marketed small-molecule drug.

Drug Discovery: Computational Approaches

Explores the EXSCALATE4COV project, focusing on computational drug discovery for COVID-19 treatments and the collaboration between academia and industry.

Preclinical Animal Models: Selection & Rationale

Explores the selection and rationale behind preclinical animal models in drug discovery, emphasizing understanding mechanisms of action and domain specificity.